QIAGEN N.V. (QGEN) bonds
QGENNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 20, 2026Score 10/30
$49.75−0.06 (-0.12%)
Close on Nov 17, 2026Market cap $10.79BP/E 25.6Yield 0.50%
Debt
Borrowings on the balance sheet, Dec 31, 2025
Total debt
$1.65B
$0 due within a year
Net debt
$815.42M
After $839.01M of cash
Implied interest rate
2.18%
FY2025 interest ÷ average debt
Interest coverage
14.0×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2025
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Qiagen's 20-F for the period ended Dec 31, 2025
| Issue | Coupon | Matures | Amount issued | Carrying value |
|---|---|---|---|---|
| 0.000% Senior Unsecured Convertible Notes due 2027 Convertible at $81 a share | 0.00% | 2027 | $26.00M | $26.00M |
| 2.500% Senior Unsecured Convertible Notes due 2031 Convertible at $64 a share | 2.50% | 2031 | $500.00M | $495.25M |
| 2.000% Senior Unsecured Convertible Notes due 2032 Convertible at $65 a share | 2.00% | 2032 | $750.00M | $742.39M |
| German Private Placement (2017 Schuldschein) | – | – | $17.04M | $17.03M |
| German Private Placement (2022 Schuldschein) | – | – | $374.23M | $373.75M |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 20-F.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size |
|---|---|
| ESG-Linked Revolving Credit Facility | €400.00M |
| Line of Credit | €13.00M |
| Line of Credit | $8.20M |
See a number that looks wrong?